unyoke

Hello and welcome to our little slice of the World, a place where passion and opinions run high in our niche area, which just so happens to be the world of patents, innovation, technology, business and other areas of intellectual property. Although Lewis Lee, our founder, is a patent attorney, and many of the contributors to our content are IP counselors, the content should NOT be considered to be legal advice, but rather are intended to be informational. No attorney-client relationship is established through your use of IP Street. For more information please check our Disclaimer, Terms & Conditions and our Privacy Policy.

Here at IPstreet.com, we want to change the story. In fact, we want to help inventors get beyond (1) conceptualization and through the important stages of (2) gestation, (3) early incubation, and (4) late incubation. To help you and your inventions, we also need to help those who support the invention process: patent attorneys, IP portfolio managers, senior executives, and investors. We believe you are the engine that drives economic development, and the supporting cast fuels the innovation process. In this section, you will learn more about how your inventions can be protected and commercialized. Whether you are a new inventor or are a patenting guru, we hope you will find our resources relevant and practical. Our content is developed by subject matter experts in business and IP law; an uncommon union of PhDs and JDs to help you make sense of the IP landscape in the development of your invention, and its ultimate commercialization.

Proper organization of a patent porfolio is essential to be prepared to properly navigate the IP landscape. One key issue is related to inventorship. Consider the Pfizer patent, patent # 5,760,06^, which is commonly known as the COX-2 inhibitor. Pfizer is currently in a $1B lawsuit because Searle, the original owner of the patent, failed to include a key inventor on the patent. Pfizer inherited this mess when they acquired Pharmacia, who had previously acquired Monsanto, who had previously acquired Searle. Ignorance is not a defensible excuse in patent litigation.